DEA Strips Oklahoma Doctor of Drug Prescription Rights
Published Date: 4/16/2025
Notice
Summary
Dr. Henry-Norbert O. Ndekwe from Oklahoma lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration, which expired on October 31, 2024. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA revokes registrations without state authority
Under 21 U.S.C. 824(a)(3), the DEA will revoke a practitioner's registration if the practitioner no longer has state authority to handle controlled substances. If your state license is suspended, revoked, or otherwise expired so you are not authorized to dispense controlled substances, you become ineligible to maintain a DEA registration and lose the legal right to prescribe or handle controlled drugs.
Dr. Ndekwe’s DEA registration revoked
The DEA revoked Henry-Norbert O. Ndekwe, M.D.'s Certificate of Registration No. BN5794587 and denied any pending applications to renew, modify, or obtain additional registration in Oklahoma. The agency noted his Oklahoma medical license expired on June 1, 2023, his DEA registration had expired on October 31, 2024, he did not request a hearing, and the Order is effective May 16, 2025. He may file a motion for reconsideration of the Agency's factual finding within fifteen calendar days to dispute the official notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-06419 — Optimize Growth Equity Fund, Optimize Premium Yield Fund and Optimize Wealth Management Inc.
Optimize Growth Equity Fund, Optimize Premium Yield Fund, and Optimize Wealth Management Inc. want permission to offer investors monthly chances to sell back their shares, instead of less often. This change could make it easier and quicker for investors to get their money when they want. The SEC will decide by May 6, 2025, unless someone asks for a hearing.
Next: 2025-06422 — Agency Information Collection Activities: Proposed Request and Comment Request
The Social Security Administration wants your thoughts on their plan to keep and improve how people submit documents online using eSignatures and uploads. This update aims to make things easier and faster for everyone who deals with Social Security, with no new costs expected. You’ve got until June 16, 2025, to share your ideas and help shape the future of these digital services!